Target intelligence / Profile preview

KTI12 chromatin associated homolog (KTI12)

Target
KTI12
Molecular classification
Chromatin-associated protein, ATP-binding protein, Elongator complex-associated protein, Other (tRNA modification factor)
01

Overview

KTI12 chromatin associated homolog (KTI12) encodes a conserved ATP-binding protein that physically and functionally associates with the Elongator complex, a six-subunit histone acetyltransferase which modifies chromatin and regulates transcription elongation. KTI12 stimulates Elongator’s activity in tRNA wobble uridine modification and is essential for correct tRNA decoding, protein translation, and cell growth in yeast. The protein contains conserved motifs such as a P-loop (NTP binding) and calmodulin-binding domains, has weak direct association with disease, and is not a drug target. Loss-of-function or mutant alleles cause tRNA modification defects and Elongator-related phenotypes, but KTI12 has not been described as a direct pharmacological target or biomarker in humans. KTI12’s main biological role is supporting tRNA modification via the Elongator complex, impacting translation efficiency and accuracy. Variants or mutations in human KTI12 are linked to rare inherited disorders but have not been therapeutically targeted. The yeast KTI12 protein has served as a genetic and mechanistic tool for studying chromatin regulatory pathways and protein translation but is not implicated in canonical signaling, receptor biology, or small molecule drug action. If structured information for clinical pharmacology or biomarker purposes is needed, KTI12 would be classified under chromatin-associated regulatory factors rather than as a receptor, enzyme, transporter, or common drug target.

Other names
SBBI81TOT4LOC6829101110001A12RikKTI12 chromatin associatedKTI12 homolog, chromatin associatedprotein KTI12 homologMGC20419
02

Biological functions

tRNA wobble uridine modificationATP bindingChromatin associationRegulation of Elongator complex activityProtein-protein interactions for chromatin and tRNA modification
03

Disease associations

Leukodystrophy, hypomyelinating, type 3Nephrolithiasis/osteoporosis, hypophosphatemic, type 2Other (based on gene associations; not a well-established direct disease driver)

Beyond the preview

Go deeper on KTI12 chromatin associated homolog (KTI12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KTI12 chromatin associated homolog (KTI12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call